Combination nanoparticle and drug approach for pancreatic cancer
Combination Therapy for Pancreatic Cancer
A tiny nanoparticle that carries gemcitabine plus a second drug aims to get more medicine into pancreatic tumors and strengthen the immune attack for people with advanced pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11294312 on NIH RePORTER |
What this research studies
You would hear about a very small drug carrier called PGEM that links gemcitabine to a polymer to make 13 nm particles that protect the drug and help it reach tumors. The team uses PGEM to carry gemcitabine together with a second drug (a CCR2 blocker) so both drugs can penetrate the dense pancreatic tumor tissue better. Early laboratory and animal results showed better tumor delivery and more tumor-fighting CD8+ T cells but also more suppressive myeloid cells, so researchers will refine the combination and study how it affects tumor control and side effects. If development progresses, the approach could move toward early human testing at clinical sites.
Who could benefit from this research
Good fit: Ideal candidates would be people with locally advanced or metastatic pancreatic cancer who are eligible for combination chemotherapy and clinical trials at the treating center.
Not a fit: People with early-stage pancreatic cancer treated with surgery alone or those who cannot tolerate chemotherapy are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could deliver chemotherapy more effectively into pancreatic tumors, shrink tumors better, and potentially lower some side effects.
How similar studies have performed: Other nanoparticle approaches such as albumin-bound paclitaxel (Abraxane) plus gemcitabine showed only limited benefit and substantial toxicity in patients, while this much smaller PGEM nanoparticle is a newer strategy with promising preclinical results but not yet proven in people.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Li, Song — University of Pittsburgh at Pittsburgh
- Study coordinator: Li, Song
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.